ClinicalTrials.gg

Program

eciskafusp alfa

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms, led by Hoffmann-La Roche.

Furthest: phase 1, since Mar 9, 20202 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche20 open or runningphase 1since Mar 9, 2020Mar 9, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2020First study: phase 1 study in Solid TumorsFirst studyNCT04303858 · 189 enrolled · Belgium, Denmark, Netherlands and more
  2. Feb 4, 2025Phase 1 study in Non-Muscle Invasive Bladder NeoplasmsNCT06816017 · Australia, Italy, Malaysia and more

TargetBeta

PDCD1 →read by rule
“A recombinant fusion protein comprised of an antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06816017Non-Muscle Invasive Bladder Neoplasms · Australia, Italy, Malaysia and more1WithdrawnOct 31, 20280
NCT04303858Solid Tumors · Belgium, Denmark, Netherlands and more1TerminatedOct 2, 2025189

How it is read

Names in the registry

  • “Eciskafusp Alfa”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.